Analyst Price Targets — MYO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 1:13 pm | Craig Knickerbocker | Craig-Hallum | $1.10 | $0.68 | StreetInsider | Myomo Inc. (MYO) PT Lowered to $1.10 at Craig-Hallum: "remains a show me story" |
| June 23, 2025 1:35 pm | — | Craig-Hallum | $8.00 | $2.27 | TheFly | Myomo price target lowered to $8 from $10 at Craig-Hallum |
| March 11, 2025 12:57 pm | — | Craig-Hallum | $11.00 | $5.87 | TheFly | Myomo price target raised to $11 from $9 at Craig-Hallum |
| July 31, 2024 7:01 am | Chase Knickerbocker | Craig-Hallum | $7.00 | $4.44 | TheFly | Myomo initiated with a Buy at Craig-Hallum |
| July 10, 2024 3:33 pm | Scott Henry | Industrial Alliance Securities | $5.75 | $4.97 | TheFly | Myomo price target raised to $5.75 from $5.25 at Alliance Global Partners |
| May 20, 2024 8:41 am | Ben Haynor | Lake Street | $3.50 | $1.82 | TheFly | Myomo initiated with a Buy at Lake Street |
Latest News for MYO
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026 at the Lotte Palace Hotel in New York.…
Myomo NYSEAMERICAN: MYO reported second-quarter 2026 revenue growth of 21% as the wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships.
Myomo, Inc. (MYO) Q2 2026 Earnings Call Transcript
Myomo, Inc. (MYO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.11 per share a year ago.
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2026. “I am pleased to report that the evolution of our go-to-market approach is driving…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MYO.
U.S. House Trading
No House trades found for MYO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.